AstraZeneca Confident For Next Decade Despite Upcoming Patent Cliff

Misses Q4 Sales Consensus Estimate

The UK major believes it can maintain growth trajectory through novel combinations regimens and pipeline diversification despite the anticipated expiration of several blockbuster drug patents over the next decade.  

Grey cliff against a light yellow sky, mountains in background
Soriot Remained Unfazed By The Prospect Of A Patent Cliff • Source: Shutterstock

AstraZeneca PLC is shifting its focus to new drug candidates and new regimens of established products as it gears up for a patent cliff starting in 2026 which could slow down its recent run of strong growth.

The firm’s fourth quarter sales dipped by 6%to $10.79bn – impacted by currency effects – and coming in 1% shy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.